{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:11:57Z","timestamp":1773645117968,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a risk prediction model for Chemical cystitis in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing intravesical instillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively enrolled 225 patients with NMIBC who received intravesical instillation between January 2024 and January 2026. Predictive variables, including demographic characteristics, oncological features, medical history, treatment-related factors, and procedural anatomy, were collected. Feature selection was performed using the Least Absolute Shrinkage and Selection Operator (LASSO) regression from 18 candidate variables. A multivariable logistic regression model was constructed based on the selected variables and visualized as a risk prediction nomogram. The model\u2019s performance was evaluated and validated using the Area Under the Curve (AUC), calibration curves, and Decision Curve Analysis (DCA) to assess discrimination, calibration, and clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five independent predictors were identified from the candidate variables through LASSO and multivariable logistic regression analysis: type of instillation agent, tumor multifocality, retention time of the agent, bladder capacity, and tumor grade. The predictive model demonstrated robust discriminative ability in both the training and validation cohorts, with AUC values of 0.840 and 0.868, respectively. Calibration curves showed high consistency between the predicted and observed risks, and DCA further confirmed the model\u2019s positive net benefit in clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We successfully developed and validated a practical nomogram for the individualized prediction of Chemical cystitis risk in patients with NMIBC. This tool can assist clinicians in identifying high-risk patients prior to treatment, thereby enabling more targeted monitoring and preventive strategies. This study is limited by its single-center retrospective design, and external prospective validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/or.2026.1791893","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:08Z","timestamp":1773643208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a risk prediction model for chemical cystitis in patients with non-muscle-invasive bladder cancer undergoing intravesical instillation"],"prefix":"10.3389","volume":"20","author":[{"given":"Xinyu","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Urology, Xiangtan Central Hospital","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangtan Central Hospital","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangtan Central Hospital","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus calmette-gu\u00e9rin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille calmette-gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0302-2838(03)00357-9","article-title":"Maintenance bacillus calmette-guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.21873\/invivo.12360","article-title":"Single short retention instillation of pirarubicin prevents intravesical recurrence of low-risk non muscle invasive bladder cancer","volume":"35","author":"Kageyama","year":"2021","journal-title":"In Vivo"},{"key":"B14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/0115748936288453240124082031","article-title":"Integrated machine learning algorithms for stratification of patients with bladder cancer","volume":"19","author":"He","year":"2024","journal-title":"Curr Bioinformatics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","article-title":"Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification","volume":"22","author":"Olislagers","year":"2025","journal-title":"Nat Rev Urol"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1791893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:09Z","timestamp":1773643209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1791893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":15,"alternative-id":["10.3389\/or.2026.1791893"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1791893","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1791893"}}